|1.||Liu, Shuang: 2 articles (12/2009 - 06/2009)|
|2.||Lindenberg, Liza: 1 article (10/2014)|
|3.||Bratslavsky, Gennady: 1 article (10/2014)|
|4.||Sherry, Richard: 1 article (10/2014)|
|5.||Somer, Ed J: 1 article (10/2014)|
|6.||Miller, Matthew P: 1 article (10/2014)|
|7.||Owenius, Rikard: 1 article (10/2014)|
|8.||Shih, Joanna: 1 article (10/2014)|
|9.||Macholl, Sven: 1 article (10/2014)|
|10.||Choyke, Peter: 1 article (10/2014)|
06/01/2009 - "(18)F-labeled RGD analogs ([(18)F]-AH111585 and [(18)F]Galacto-RGD) have been investigated in clinical trials for positron emission tomography (PET) imaging of integrin expression in cancer patients. "
01/01/2009 - "This study describes the favorable in vivo kinetics and tumor-targeting properties of 18F-AH111585, a novel 18F-RGD peptide, and its ability to monitor tumor vascularity noninvasively. "
01/01/2009 - "18F-AH111585 is a promising 18F-labeled RGD tracer that offers a new approach to noninvasively image tumor vasculature. "
01/01/2009 - "Biodistribution of 18F-AH111585 demonstrated rapid clearance from the blood and key background organs and good tumor accumulation, with 1.5 percentage injected dose per gram (%ID/g) present at 2 h after injection in LLC tumors. "
01/01/2009 - "Tumor uptake of 18F-AH111585 and microvessel density were then assessed. "
|2.||Breast Neoplasms (Breast Cancer)
06/01/2008 - "The biodistribution of 18F-AH111585 was assessed in 18 tumor lesions from 7 patients with metastatic breast cancer by PET, and the PET data were compared with CT results. "
06/01/2008 - "Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients."
06/01/2008 - "18F-AH111585 designed to bind the alpha v beta3 integrin is safe, metabolically stable, and retained in tumor tissues and detects breast cancer lesions by PET in most anatomic sites."
06/01/2008 - "We have assessed the safety, stability, and tumor distribution kinetics of a novel radiolabeled RGD-based integrin peptide-polymer conjugate, 18F-AH111585, and its feasibility to detect tumors in metastatic breast cancer patients using PET. "
|3.||Neoplasm Metastasis (Metastasis)
06/01/2008 - "All 18 tumors detected by CT were visible on the 18F-AH111585 PET images, either as distinct increases in uptake compared with the surrounding normal tissue or, in the case of liver metastases, as regions of deficit uptake because of the high background activity in normal liver tissue. "
|5.||Melanoma (Melanoma, Malignant)
|2.||Integrin beta3 (GPIIIa)